节肢动物传播病毒感染检测市场（依检测类型、技术、最终用户、样本类型和疾病类型划分）－全球预测，2025-2032年

预计到 2032 年，节肢动物传播病毒感染检测市场将成长至 284.7 亿美元，复合年增长率为 11.19%。

主要市场统计数据
基准年 2024	121.8亿美元
预计年份：2025年	135.2亿美元
预测年份：2032年	284.7亿美元
复合年增长率 (%)	11.19%

制定一套全面的框架，涵盖诊断优先事项、操作要务和协作方法，以应对节肢动物传播的病毒威胁。

节肢动物传播的病毒感染疾病呈现出复杂且不断变化的诊断格局，涉及临床紧迫性、公共卫生监测和快速发展的技术三者。本执行摘要概述了目前临床医生、实验室负责人和政策制定者面临的挑战，因为媒介传播病原体持续需要细緻入微的诊断应对。目前的诊断重点不仅包括及时检测病原体，还包括区分急性感染和先前感染、在流行地区进行多重鑑定以及整合监测数据以指导公共卫生干预措施。

在临床实务中，诊断流程正在重新调整，以期在维持快速性和成本效益的同时，提高检测的敏感度和特异性。临床实验室必须权衡抗体检测（提供血清状态资讯）、抗原检测（提供快速照护现场能力）和分子检测（能够明确鑑定病原体）之间的优缺点。同时，监测系统需要来自不同终端使用者（包括医院实验室、参考文献中心和学术机构）的标准化资料流，以建立可操作的流行病学资讯。

这项措施凸显了製定一套协调一致的策略的必要性，该策略应将诊断创新与实际操作、监管要求和供应链考量相结合。它确立了这样一个前提：有效应对节肢动物传播病毒取决于在不同环境中策略性地部署检测，谨慎选择适合临床问题的检测技术，以及公共卫生机构与诊断技术研发人员之间的持续合作。

技术融合、数据互通性和弹性供应链如何重塑诊断方法以及公共卫生部门对虫媒病毒疾病的应对措施

受技术创新、流行病学变化以及相关人员期望转变的驱动，节肢动物传播病毒的检测格局正在发生显着变化。核酸扩增方法的进步拓展了分子检测的应用范围，使其不再局限于中心实验室，从而实现了床边检测平台，兼具快速出结果和强大的分析性能。同时，免疫测量方法和侧向层析技术的改进也提升了抗体和抗原检测在照护现场和分散式检测环境中的效用。

除了检测方法的创新之外，数据整合正在改变诊断的价值提案。即时数据流和可互通的报告系统增强了监测能力，并加快了疫情爆发的检测速度。同时，多重检测和综合症检测也日益受到重视，这些检测能够解决多种虫媒病毒流行地区常见的合併感染和重迭的临床表现。监管机构也不断完善相关管道，以支援在紧急情况下快速部署有效的检测方法，同时确保品质和安全标准。

供应链韧性和生产敏捷性已成为策略规划的核心。诊断技术开发商正投资于多元化采购和模组化生产方式，以降低中断风险。这些转变反映了诊断生态系统正朝着更具适应性、网络化的模式发展，在这个生态系统中，技术能力、数据连接、监管协调和供应链稳健性共同作用，重塑了节肢动物传播病毒感染的检测和管理方式。

评估2025年关税对诊断采购、供应链韧性和製造在地化策略的系统性影响

美国将于2025年开始实施的累积关税对诊断侦测基础设施、采购动态和供应链策略产生了多方面的影响。试剂、检测盒和仪器组件等关键零件进口成本的上升迫使许多诊断服务提供者和实验室重新评估筹资策略。为此，一些製造商加快了关键生产能力的本地化进程，而另一些製造商则重新谈判了供应商合约或修改了产品设计，以减少对受关税影响的原材料的依赖。

这些调整导致整个诊断生态系统的运作发生变化。临床实验室和参考机构重新评估了采购週期，优先考虑与供应商建立长期伙伴关係，并加强库存管理以减轻短期价格波动的影响。公共卫生计画评估了采购流程，重点在于供应商多元化和疫情爆发前的紧急计画。同时，政府采购和监管机构开展对话，力求在贸易政策目标与公共卫生需求之间取得平衡，并鼓励在特定情况下对生命攸关的医疗用品给予豁免和临时救济。

关税环境也影响了诊断公司在生产布局和供应链冗余方面的策略决策。一些公司加快了对国内或近岸生产的投资，以确保重点检测组件的持续供应，而另一些公司则寻求联合生产安排以分散风险。 2025年贸易政策转变的累积影响，进一步凸显了供应链透明度、弹性生产和采购管治在保障诊断能力、抵御节肢动物传播病毒威胁的战略重要性。

整合細項分析，将测试类型、技术平台、检体基质、最终用户需求和病原体特异性诊断管道连结起来

关键的细分洞察阐明瞭如何选择检测策略和技术以协调临床、实验室和监测目标。在考虑检测类型时，相关人员必须权衡抗体检测、抗原检测和分子检测的互补作用。抗体检测，包括区分IgG和IgM抗体的检测方法，可提供有关免疫史和暴露模式的重要信息，从而支持血清学监测和回顾性病例分类。抗原检测，包括酵素结合免疫吸附（ELISA）抗原检测和快速抗原检测方法，在临床分流和照护现场决策方面具有实际优势。分子检测方法，包括常规PCR、等温扩增和即时PCR ，仍然是病原体确诊和基因分型的黄金标准，对于急性病例确诊和基于序列的监测至关重要。

技术选择进一步提升了诊断效能和易用性。从化学发光免疫分析到酵素连结免疫检测(ELISA) 和侧向层析免疫检测，免疫检测平台提供了广泛的规模、通量和部署选择。化学冷光定序技术，包括 Illumina 定序和焦磷酸测序，能够对病原体进行详细的特性分析和基因组监测，特别适用于追踪病毒的演化和传播途径。基于 PCR 的技术涵盖了从常规 PCR 和即时PCR到等温扩增技术，从而促进了分散式分子诊断。快速诊断测试，例如横向流动化验和光学免疫检测，在临床第一线环境中具有快速且方便的优势。

最终用户细分影响着采购和部署策略。学术和研发机构优先考虑支援检测开发和基因组研究的平台，而医院实验室和诊断中心则更注重通量、週转时间和与临床工作流程的整合。参考实验室在确诊检测和品质保证中发挥核心作用，在区域网路中提供标准化检测和专业服务。检体类型（血清、脑脊髓液、血浆、唾液和全血）的选择决定了检体处理通讯协定、检测灵敏度和临床效用，从而为每种疾病选择特定的检体基质。最后，基孔肯雅热、登革热、西尼罗河病毒、黄热病和兹卡等疾病类型的细分决定了诊断演算法。有些病原体在急性期需要分子确诊，而有些病原体则主要依赖血清学结果进行后期诊断和监测。

了解这些多层次细分的动态将使决策者能够根据临床需求、监测目标和操作能力来客製化诊断服务，并认识到测试类型、技术、最终用户、样本类型和目标疾病之间的互通性和互补性。

世界各地不同的诊断需求和基础设施现状将影响技术采用、监测重点和区域实施方法。

区域动态影响诊断策略的优先排序和实施。在美洲，公共卫生机构和实验室网路正面临着都市区和农村地区多样化的流行病学压力，因此需要灵活的诊断方法，将快速筛检与有针对性的确诊检测相结合。需求驱动因素包括疫情应对准备、跨境监测以及维持对共同流行的虫媒病毒的检测能力。因此，重点在于投资于能够扩展并适应不断变化的病例数，同时通常也支援综合报告系统的平台。

欧洲、中东和非洲各地医疗保健系统和资源环境的差异导致了不同的技术应用模式。位于城市中心和参考网路中的大型实验室倾向于利用先进的分子和定序技术进行病原体精确鑑定，而分散的医疗机构则优先考虑经济高效的快速诊断和完善的品质保证系统。该地区的监测重点通常在于加强样本发放管道和协调检体流程，以支援及时发现疫情和促进跨区域合作。

在亚太地区，某些地区虫媒病毒的流行以及检测能力的快速发展，推动了对多重诊断的高需求，并促使各国大力投资照护现场解决方案。拥有成熟工业基础和製造能力的国家正在推动国内生产和技术转让，以增强自主研发能力；而其他国家则致力于建立实验室网路和加强培训，以扩大分子检测能力。根据不同地区的具体情况，基础设施、法规环境和流行病学之间的相互作用将决定哪些技术和交付模式最为可行。

诊断公司之间的竞争动态和策略倡议，重点在于产品组合广度、伙伴关係、监管准备和供应链敏捷性。

在节肢动物传播病毒检测领域，企业层面的动态动态揭示了几个相互交织的主题，这些主题正在影响企业的竞争定位和创新轨迹。在该领域，各公司都在投资涵盖快速抗原检测、高通量免疫测量和分子平台等综合产品系列，以满足临床和监测环境中的各种应用需求。策略伙伴关係和共同开发契约已成为加速检测检验、拓展分销管道以及整合互补技术能力的常用途径。

製造商日益重视品质系统、法规遵循和上市后监测，以确保效用并赢得实验室客户的信任。为了减少停机时间并优化各种环境下的侦测效能，企业正着力完善客户支援体系，包括培训、能力验证和远距离诊断。此外，具备定定序和生物资讯能力的公司正在拓展服务，将诊断结果与可操作的流行病学资讯结合，从而增强其对公共卫生客户和大型诊断网路的价值提案。

供应链优化和製造敏捷性仍然是企业竞争优势的关键。拥有多元化供应商基础、近岸生产选择以及灵活的製造外包关係的企业，能够更好地应对采购中断和政策变化。此外，随着诊断技术日益融入更广泛的医疗资讯生态系统，对资料互通性、云端彙报和网路安全措施的投资也逐渐成为业界标准。

诊断领域领导者可采取切实可行的策略步骤和营运重点，以加强其产品组合、供应链、监管沟通和数据整合。

针对行业领导者的实际建议着重于使技术选择与营运实际情况和策略韧性相契合。优先考虑均衡的产品组合策略，整合快速抗原解决方案、强大的免疫检测平台和便利的分子诊断技术，以满足急性临床需求、血清学监测和确证检测要求。在产品多样化的基础上，辅以服务导向能力，例如培训、能力验证计划和远端技术支持，以促进产品应用并在各种用户环境中保持品质。

投资于供应链透明度和生产灵活性，以缓解防控措施带来的成本压力和物流中断。考虑对关键试剂和组件采用近岸或冗余生产安排，并建立策略供应商伙伴关係，以确保生产连续性。透过采用标准化报告表格和安全资料传输通讯协定，增强资料互通性，确保诊断结果能够有效为公共卫生监测和临床决策支援系统提供资讯。

我们正积极与监管机构合作，简化紧急诊断的检验流程，并确保在疫情爆发期间有条件进入。我们正在扩大与公共卫生实验室、学术机构和参考网络的倡议，以验证不同检体类型和疾病背景下的检测方法。最后，我们正在建立持续学习机制，收集真实世界的绩效数据和相关人员的回馈，以指导产品迭代改进和服务提升。

透过结合专家访谈、技术文献综述和多层次品质保证的稳健混合方法检验研究结果。

本报告的调查方法结合了三管齐下的证据收集、专家咨询和严格的品管，以确保分析的可靠性。主要研究包括对临床实验室主任、分子和免疫检测专家、公共卫生专业人员以及采购专家进行结构化访谈，以获取关于各环境下运营限制、技术偏好和实施障碍的第一手观点。次要研究资料包括同行评审文献、监管指导文件、技术白皮书和公开的监测资料集，用于为主要研究成果提供背景资讯并检验技术论点。

分析过程包括建立一个系统框架以整合不同的资料流，随后进行定性综合分析，以突出主题优先事项，例如检测选择标准、检体处理注意事项和供应链脆弱性。品质保证措施包括将访谈结果与已记录的性能特征进行交叉检验、由独立专家进行迭代审查以及一致性检查，以确保术语的准确性和调查方法的透明度。我们也承认存在一些局限性，例如区域报告实践的差异以及政策环境的变化可能会影响实施结果。在条件允许的情况下，我们着重强调研究观察的相对优先顺序和操作意义，而非绝对指标，以便为实验室负责人和卫生计画管理人员提供可操作的决策支援。

战略要务综合强调技术整合、系统韧性和数据主导的协作方法，以实现持续的诊断准备。

总之，针对节肢动物传播病毒感染疾病的诊断应对正处于曲折点，其特点是技术能力的快速提升、对供应链韧性的重视以及对数据驱动型监测日益增长的期望。有效的策略取决于整合互补的检测类型——抗体检测、抗原检测和分子检测——同时根据不同的最终用户和检体情况选择合适的技术。政策制定者和采购负责人必须在快速取得诊断结果和长期系统永续性之间取得平衡，优先考虑灵活的生产方式和可靠的供应。

相关人员应将互通性和数据整合视为现代诊断生态系统的核心支柱，从而能够将检测结果快速转化为公共卫生行动。透过投资培训、品质系统和协作检验工作，该领域可以提高诊断信心，并更好地应对未来虫媒病毒带来的挑战。展望未来，结合技术创新、严谨营运和跨部门合作的适应性策略对于在最关键的时刻和地点提供及时、准确和可操作的诊断资讯至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 整合多重PCR检测板，用于同时检测登革热、基孔肯雅热和兹卡病毒
• 推出可携式即时诊断设备，用于检测虫媒病毒。
• 扩大与智慧型手机连接的蚊媒病毒家用检测套组的范围
• 实施人工智慧驱动的预测分析平台，用于即时疫情监测和检测优先排序
• 开发新一代血清学检测方法，以区分地方性流行区中存在交叉反应的黄病毒抗体
• 诊断公司与世界卫生组织伙伴关係，在资源匮乏地区进行可扩展的虫媒病毒检测。
• 监管部门的核准加速了用于大规模虫媒病毒筛检的高通量自动化平台的商业化进程
• 奈米孔定序技术在蚊媒病毒现场直接RNA鑑定的研究进展
• 建立节肢动物传播病毒监测实验室网络，并增加政府对基因组监测的资助。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依检测类型分類的节肢动物传播病毒感染检测市场

• 抗体检测
  • IgG抗体
  • IgM抗体
• 抗原检测
  • ELISA抗原
  • 快速抗原
• 分子检测
  • 常规PCR
  • 等温扩增
  • 即时PCR

9. 按技术分類的节肢动物传播病毒感染检测市场

• 免疫检测
  • 化学冷光免疫检测
  • ELISA
  • 侧向流动免疫检测
• 下一代定序
  • Illumina定序
  • 焦磷酸测序
• 基于PCR的技术
  • 常规PCR
  • 等温扩增
  • 即时PCR
• 快速诊断测试
  • 横向流动化验
  • 光学免疫检测

第十章 依最终用户分類的节肢动物传播病毒感染检测市场

• 学术机构
• 诊断中心
• 医院检查室
• 参考实验室
• 研究所

第十一章 依样本类型分類的节肢动物传播病毒感染检测市场

• 血清
• 脑脊髓液
• 电浆
• 唾液
• 全血

第十二章 依疾病类型分類的节肢动物传播病毒感染检测市场

• 基孔肯雅热
• 登革热
• 西尼罗河热
• 黄热病
• 兹卡热

13. 各地区节肢动物传播病毒感染检测市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 节肢动物传播病毒感染检测市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

15. 各国节肢动物传播病毒感染检测市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • bioMerieux SA
  • DiaSorin SpA
  • Bio-Rad Laboratories, Inc.
  • Abnova Corporation
  • AdvaCare Pharma
  • Chembio Diagnostics, Inc.
  • EUROIMMUN AG by PerkinElmer Inc.

The Arthropod-borne Viral Infections Testing Market is projected to grow by USD 28.47 billion at a CAGR of 11.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 12.18 billion
Estimated Year [2025]	USD 13.52 billion
Forecast Year [2032]	USD 28.47 billion
CAGR (%)	11.19%

Comprehensive framing of diagnostic priorities, operational imperatives, and collaborative approaches to address arthropod-borne viral threats

Arthropod-borne viral infections present a complex and evolving diagnostic landscape that intersects clinical urgency, public health surveillance, and rapid technological advancement. The introduction to this executive summary frames the contemporary challenges faced by clinicians, laboratory leaders, and policymakers as vector-borne pathogens continue to demand nuanced diagnostic responses. Diagnostic priorities now include not only timely pathogen detection but also differentiation between acute and past infections, multiplexed identification in co-endemic settings, and integration of surveillance data to guide public health interventions.

Across clinical environments, diagnostic workflows are being rebalanced to achieve higher sensitivity and specificity while preserving speed and cost-effectiveness. Laboratories must weigh the trade-offs among antibody assays that provide serostatus context, antigen tests that offer rapid point-of-care functionality, and molecular modalities that deliver definitive pathogen identification. Concurrently, surveillance systems require standardized data streams from diverse end users such as hospital laboratories, reference centers, and academic institutions to construct actionable epidemiologic intelligence.

This introduction underscores the need for cohesive strategies that align diagnostic innovation with operational realities, regulatory requirements, and supply chain considerations. It establishes the premise that effective responses to arthropod-borne viruses will depend on strategic deployment of tests across settings, careful selection of technologies appropriate to clinical questions, and continuous collaboration between public health authorities and diagnostic developers.

How technological convergence, data interoperability, and resilient supply chains are reshaping diagnostics and public health responses to arboviral disease

The landscape for arthropod-borne viral testing is undergoing transformative shifts driven by technological innovation, changing epidemiology, and evolving stakeholder expectations. Advances in nucleic acid amplification methods have expanded the practicality of molecular testing beyond centralized laboratories, enabling near-patient platforms that combine shortened time-to-result with robust analytical performance. At the same time, improvements in immunoassay formats and lateral flow designs have enhanced the utility of antibody and antigen testing in both point-of-care and decentralized settings.

Beyond assay innovation, data integration is altering diagnostic value propositions. Real-time data streams and interoperable reporting systems strengthen surveillance capabilities and accelerate outbreak detection. This trend is complemented by an increased emphasis on multiplexing and syndromic panels that can resolve coinfections and overlapping clinical presentations common in regions with multiple circulating arboviruses. Regulatory authorities are also refining pathways to support rapid deployment of validated tests during emergent situations while maintaining quality and safety standards.

Supply chain resilience and manufacturing agility have become central to strategic planning. Diagnostic developers are investing in diversified sourcing and modular production approaches to mitigate disruptions. Collectively, these shifts reflect a move toward more adaptive, networked diagnostic ecosystems where technological performance, data connectivity, regulatory alignment, and supply chain robustness converge to reshape how arthropod-borne viral infections are detected and managed.

Assessing the systemic consequences of 2025 tariff measures on diagnostics procurement, supply chain resilience, and manufacturing localization strategies

The introduction of cumulative tariffs by the United States in 2025 has exerted multifaceted effects across diagnostic testing infrastructure, procurement dynamics, and supply chain strategies. Rising import costs for key components such as reagents, assay cartridges, and instrument subassemblies have compelled many diagnostic providers and laboratories to reassess sourcing strategies. In response, some manufacturers accelerated localization of critical production capacity, while others renegotiated supplier contracts or adapted product designs to reduce reliance on tariff-impacted inputs.

These adjustments have translated into operational changes across the diagnostic ecosystem. Clinical laboratories and reference facilities re-evaluated procurement cycles, prioritizing long-term supplier partnerships and inventory management practices that buffer short-term price volatility. Public health programs assessing procurement for outbreak preparedness emphasized supplier diversity and contingency planning. At the same time, government procurement agencies and regulatory bodies engaged in dialogue to balance trade policy objectives with public health imperatives, encouraging exemptions or temporary relief for life-critical medical goods in certain circumstances.

The tariff environment also influenced strategic decision-making for diagnostic companies considering investments in manufacturing footprint and supply chain redundancy. Some organizations accelerated investment in domestic or near-shore production to ensure continuity for high-priority assay components, while others pursued collaborative manufacturing agreements to distribute risk. Ultimately, the cumulative impact of trade policy shifts in 2025 reinforced the strategic importance of supply chain visibility, flexible manufacturing, and procurement governance in safeguarding diagnostic readiness for arthropod-borne viral threats.

Integrated segmentation analysis linking test types, technology platforms, specimen matrices, end-user requirements, and pathogen-specific diagnostic pathways

Key segmentation insights illuminate how testing strategies and technology choices must be tailored to clinical, laboratory, and surveillance objectives. When considering test type, stakeholders must navigate the complementary roles of antibody testing, antigen testing, and molecular testing. Antibody testing, including assays that differentiate IgG from IgM antibodies, offers critical information about immune history and exposure patterns, which supports serosurveillance and retrospective case classification. Antigen testing, encompassing enzyme-linked immunosorbent (ELISA) antigen formats and rapid antigen approaches, delivers practical benefits for immediate clinical triage and point-of-care decision-making. Molecular testing modalities such as conventional PCR, isothermal amplification, and real-time PCR remain the gold standard for definitive pathogen detection and genotyping, and are pivotal for acute case confirmation and sequence-based surveillance.

Technology choices further refine diagnostic performance and operational fit. Immunoassay platforms-ranging from chemiluminescent immunoassays to ELISA and lateral flow immunoassays-provide scale, throughput, and diverse deployment options. Next generation sequencing technologies, including Illumina sequencing and pyrosequencing, enable in-depth pathogen characterization and genomic surveillance, particularly valuable for tracking viral evolution and transmission pathways. PCR-based technologies span conventional and real-time PCR as well as isothermal amplification techniques that facilitate decentralized molecular diagnostics. Rapid diagnostic tests, represented by lateral flow assays and optical immunoassays, deliver speed and ease-of-use for frontline settings.

End user segmentation shapes procurement and implementation strategies. Academic institutions and research institutes prioritize platforms that support method development and genomic studies, whereas hospital laboratories and diagnostic centers emphasize throughput, turnaround time, and integration with clinical workflows. Reference laboratories play a central role in confirmatory testing and quality assurance, supplying standardized testing and specialized services to regional networks. Sample type considerations-blood serum, cerebrospinal fluid, plasma, saliva, and whole blood-determine specimen handling protocols, assay sensitivity, and clinical utility, with specific sample matrices favored for different disease presentations. Finally, disease type segmentation across chikungunya, dengue, West Nile, yellow fever, and Zika dictates diagnostic algorithms; some pathogens necessitate molecular confirmation during the acute phase while others rely heavily on serologic interpretation for later-stage diagnosis and surveillance.

Understanding these layered segmentation dynamics enables decision-makers to align diagnostic offerings to clinical needs, surveillance goals, and operational capabilities while recognizing the interoperability and complementarity among test types, technologies, end users, sample types, and disease targets.

Regional diagnostic imperatives and infrastructure realities shaping technology adoption, surveillance priorities, and localized implementation approaches across global regions

Regional dynamics affect how diagnostic strategies are prioritized and operationalized. In the Americas, public health agencies and laboratory networks contend with diverse epidemiologic pressures across urban and rural contexts, necessitating flexible diagnostics that combine rapid screening with centralized confirmatory testing. Demand drivers include outbreak response readiness, cross-border surveillance, and the need to maintain laboratory capacity for co-circulating arboviruses. Consequently, investments often emphasize platforms that can scale and adapt to shifting caseloads while supporting integrated reporting systems.

Across Europe, the Middle East & Africa, heterogeneous healthcare systems and resource environments create differentiated adoption patterns. High-capacity laboratories in urban centers and reference networks tend to leverage advanced molecular and sequencing technologies for precise pathogen characterization, whereas decentralized settings prioritize cost-effective rapid diagnostics and robust quality assurance programs. Surveillance priorities in this region frequently focus on strengthening sample referral pathways and harmonizing diagnostic algorithms to support timely outbreak detection and cross-jurisdictional collaboration.

In the Asia-Pacific region, the combination of endemic arboviral transmission in certain geographies and rapidly evolving laboratory capabilities drives both high demand for multiplexed diagnostics and active investment in point-of-care solutions. Countries with established industrial bases and manufacturing capabilities pursue domestic production and technology transfer to support self-reliance, while others focus on building laboratory networks and enhancing training to expand molecular testing capacity. Across regions, the interplay between infrastructure, regulatory environments, and epidemiology shapes which technologies and implementation models are most viable.

Competitive dynamics and strategic maneuvers among diagnostic firms focusing on portfolio breadth, partnerships, regulatory readiness, and supply chain agility

Company-level dynamics in the arthropod-borne viral testing space reveal several converging themes that influence competitive positioning and innovation trajectories. Across the sector, firms are investing in integrated product portfolios that span rapid antigen assays, high-throughput immunoassays, and molecular platforms to address diverse use cases across clinical and surveillance settings. Strategic partnerships and cooperative development agreements have become common pathways to accelerate assay validation, expand distribution channels, and combine complementary technical capabilities.

Manufacturers are increasingly focused on quality systems, regulatory preparedness, and post-market surveillance to ensure sustained clinical utility and trust among laboratory customers. There is a notable emphasis on formalizing customer support infrastructures, including training, proficiency testing, and remote diagnostics to reduce downtime and optimize assay performance in varied settings. In addition, firms with capabilities in sequencing and bioinformatics are expanding offerings that link diagnostic outputs to actionable epidemiologic intelligence, thereby enhancing the value proposition for public health clients and large diagnostic networks.

Supply chain optimization and manufacturing agility remain competitive differentiators. Organizations that have established diversified supplier bases, near-shore production options, and flexible contract manufacturing relationships are better positioned to navigate procurement disruptions and policy shifts. Finally, investment in data interoperability, cloud-enabled reporting, and cybersecurity measures is becoming a standard expectation as diagnostics increasingly feed into broader health information ecosystems.

Practical strategic steps and operational priorities for diagnostic leaders to strengthen portfolios, supply chains, regulatory engagement, and data integration

Actionable recommendations for industry leaders emphasize aligning technological choices with operational realities and strategic resilience. Prioritize a balanced portfolio strategy that integrates rapid antigen solutions, robust immunoassay platforms, and accessible molecular diagnostics to cover acute clinical needs, serosurveillance objectives, and confirmatory testing requirements. Complement product diversification with service-oriented capabilities such as training, proficiency programs, and remote technical support to enhance adoption and sustain quality performance across user settings.

Invest in supply chain transparency and manufacturing flexibility to mitigate policy-driven cost pressures and logistical disruptions. Consider near-shore or redundant production arrangements for critical reagents and components, and cultivate strategic supplier partnerships to preserve continuity. Strengthen data interoperability by adopting standardized reporting formats and secure data transmission protocols so diagnostic outputs can effectively inform public health surveillance and clinical decision support systems.

Engage proactively with regulatory authorities to streamline validation pathways for emergent diagnostics and to secure conditional access during outbreak scenarios. Expand collaborative initiatives with public health laboratories, academic institutions, and reference networks to validate assays across diverse specimen types and disease contexts. Finally, embed a continuous learning cycle that captures real-world performance data and stakeholder feedback to guide iterative product improvements and service enhancements.

Robust mixed-methods approach combining primary expert interviews, secondary technical literature synthesis, and multi-stage quality assurance to validate insights

The research methodology underpinning this report combines triangulated evidence gathering, expert consultation, and rigorous quality controls to ensure analytic robustness. Primary research included structured interviews with clinical laboratory directors, molecular and immunoassay subject-matter experts, public health practitioners, and procurement professionals, enabling firsthand perspectives on operational constraints, technology preferences, and implementation barriers across settings. Secondary research sources comprised peer-reviewed literature, regulatory guidance documents, technical white papers, and publicly available surveillance datasets to contextualize primary insights and validate technical assertions.

Analytic processes applied systematic framework mapping to reconcile divergent data streams, followed by qualitative synthesis to surface thematic priorities such as assay selection criteria, specimen handling considerations, and supply chain vulnerabilities. Quality assurance measures included cross-validation of interview findings with documented performance characteristics, iterative review by independent experts, and consistency checks to ensure terminological precision and methodological transparency. Limitations are acknowledged, including variability in regional reporting practices and evolving policy environments that may affect implementation outcomes. Wherever possible, findings were framed to highlight relative priorities and operational implications rather than absolute measures, supporting actionable decision-making by laboratory leaders and health program managers.

Synthesis of strategic imperatives underscoring technology integration, system resilience, and collaborative data-driven approaches for sustained diagnostic readiness

In conclusion, the diagnostic response to arthropod-borne viral infections is at an inflection point, characterized by accelerating technological capability, heightened emphasis on supply chain resilience, and intensifying expectations for data-driven surveillance. Effective strategies will hinge on integrating complementary test types-antibody, antigen, and molecular-while matching technology selection to the needs of diverse end users and specimen contexts. Policymakers and procurement leaders must balance rapid access to diagnostics with long-term system sustainability, prioritizing flexible manufacturing and secure supply arrangements.

Stakeholders should also embrace interoperability and data integration as central pillars of modern diagnostic ecosystems, enabling rapid translation of laboratory findings into public health action. By investing in training, quality systems, and collaborative validation efforts, the sector can improve diagnostic reliability and readiness for future arboviral challenges. Looking forward, adaptive strategies that combine technological innovation, operational rigor, and cross-sector collaboration will be essential to deliver timely, accurate, and actionable diagnostic information where and when it matters most.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of multiplex PCR panels enabling simultaneous detection of dengue chikungunya and Zika viruses
• 5.2. Adoption of portable point-of-care diagnostic devices with CRISPR-based arboviral detection technology
• 5.3. Expansion of at-home test kits for mosquito-borne virus screening with smartphone connectivity
• 5.4. Implementation of AI-driven predictive analytics platforms for real-time outbreak surveillance and testing prioritization
• 5.5. Development of next-generation serological assays differentiating cross-reactive flavivirus antibodies in endemic regions
• 5.6. Partnerships between diagnostic companies and global health organizations for scalable arboviral testing in resource-limited settings
• 5.7. Regulatory approvals accelerating commercialization of high-throughput automated platforms for large-scale arbovirus screening
• 5.8. Research advances in nanopore sequencing for direct RNA identification of emerging mosquito-borne viruses in field settings
• 5.9. Increased government funding for establishing sentinel testing networks and genomic surveillance of arthropod-borne viruses

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Arthropod-borne Viral Infections Testing Market, by Test Type

• 8.1. Antibody Testing
  • 8.1.1. IgG Antibody
  • 8.1.2. IgM Antibody
• 8.2. Antigen Testing
  • 8.2.1. Elisa Antigen
  • 8.2.2. Rapid Antigen
• 8.3. Molecular Testing
  • 8.3.1. Conventional PCR
  • 8.3.2. Isothermal Amplification
  • 8.3.3. Real Time PCR

9. Arthropod-borne Viral Infections Testing Market, by Technology

• 9.1. Immunoassay
  • 9.1.1. Chemiluminescent Immunoassay
  • 9.1.2. Elisa
  • 9.1.3. Lateral Flow Immunoassay
• 9.2. Next Generation Sequencing
  • 9.2.1. Illumina Sequencing
  • 9.2.2. Pyrosequencing
• 9.3. PCR Based Technologies
  • 9.3.1. Conventional PCR
  • 9.3.2. Isothermal Amplification
  • 9.3.3. Real Time PCR
• 9.4. Rapid Diagnostic Test
  • 9.4.1. Lateral Flow Assay
  • 9.4.2. Optical Immunoassay

10. Arthropod-borne Viral Infections Testing Market, by End User

• 10.1. Academic Institutions
• 10.2. Diagnostic Centers
• 10.3. Hospital Laboratories
• 10.4. Reference Laboratories
• 10.5. Research Institutes

11. Arthropod-borne Viral Infections Testing Market, by Sample Type

• 11.1. Blood Serum
• 11.2. Cerebrospinal Fluid
• 11.3. Plasma
• 11.4. Saliva
• 11.5. Whole Blood

12. Arthropod-borne Viral Infections Testing Market, by Disease Type

• 12.1. Chikungunya
• 12.2. Dengue
• 12.3. West Nile
• 12.4. Yellow Fever
• 12.5. Zika

13. Arthropod-borne Viral Infections Testing Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Arthropod-borne Viral Infections Testing Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Arthropod-borne Viral Infections Testing Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. F. Hoffmann-La Roche Ltd.
  • 16.3.2. Abbott Laboratories
  • 16.3.3. Thermo Fisher Scientific Inc.
  • 16.3.4. bioMerieux SA
  • 16.3.5. DiaSorin S.p.A.
  • 16.3.6. Bio-Rad Laboratories, Inc.
  • 16.3.7. Abnova Corporation
  • 16.3.8. AdvaCare Pharma
  • 16.3.9. Chembio Diagnostics, Inc.
  • 16.3.10. EUROIMMUN AG by PerkinElmer Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL ARTHROPOD-